NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analog).

Topline results from the MAGNIFY phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

Insurance coverage from the second largest health plan in the US paves the way for expanded access to Luminopia’s unique amblyopia therapeutic.

New data for 0.25% reproxalap was announced by Aldeyra Therapeutics, supporting the company’s NDA resubmission for the treatment of dry eye disease.

Dilsher Dhoot, MD, FASRS, shares his forward-looking perspective on developments in retinal disease management, highlighting both recent breakthroughs and promising innovations on the horizon.

Results from the first-in-human study of SpyGlass Pharma's bimatoprost-eluting IOL showed significant reduction in IOP and improved best-corrected distance visual acuity.

According to a press release, Myatro XL is the first 0.05% atropine eye drop for pediatric myopia control. It will be commercially available in India in July 2025.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.

Good safety profile and “meaningful improvement” in vision in patient with Leber congenital amaurosis.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Paul Karpecki, OD, FAAO, sits down to discuss Sydnexis's atropine formulation and what an FDA approval would mean for myopia management.

If executed, the reverse merger would create a new ophthalmic company that pairs two FDA-approved technologies for use in glaucoma patients.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

The new device from Lumenis aids in ocular surface disease treatment by combining radio frequency and dynamic muscle stimulation to improve lower lid laxity, enhance blink dynamics, and offer a non-invasive solution for dry eye management.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

ENCELTO is the first and only FDA-approved treatment for MacTel.

The gel was investigated in a case series, which was presented in a poster at SECO 2025.

Systane PRO preservative-free is the longest lasting dry eye drop in the Systane portfolio, according to Alcon.

If approved, Epoxia will be the first epi-on corneal crosslinking on the market.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care that successfully completed a Phase 2b clinical trial.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.